{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:22:59Z","timestamp":1790662979876,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81330048"],"award-info":[{"award-number":["81330048"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81520108025"],"award-info":[{"award-number":["81520108025"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81301864"],"award-info":[{"award-number":["81301864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472292"],"award-info":[{"award-number":["81472292"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572464"],"award-info":[{"award-number":["81572464"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.canlet.2015.11.034","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T03:02:42Z","timestamp":1449198162000},"page":"171-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"title":["MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS\/RAF\/ERK signaling pathways"],"prefix":"10.1016","volume":"371","author":[{"given":"Yanmin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leina","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongli","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2015.11.034_bib0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/jhep.2003.50142","article-title":"HCC surveillance: who is the target population?","volume":"37","author":"Bruix","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.11.034_bib0015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/hep.20758","article-title":"Comparison of staging systems for HCC: one more positive answer or mission impossible?","volume":"42","author":"Huo","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.11.034_bib0020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev.med.080608.100623","article-title":"Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy","volume":"61","author":"Villanueva","year":"2010","journal-title":"Annu. Rev. Med"},{"key":"10.1016\/j.canlet.2015.11.034_bib0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/hep.23260","article-title":"Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety","volume":"51","author":"Vitale","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.11.034_bib0030","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s00535-010-0270-0","article-title":"Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives","volume":"45","author":"Shen","year":"2010","journal-title":"J. Gastroenterol"},{"key":"10.1016\/j.canlet.2015.11.034_bib0035","first-page":"2498","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Palmer","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2015.11.034_bib0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S1470-2045(08)70317-6","article-title":"Sorafenib for liver cancer: the horizon broadens","volume":"10","author":"Johnson","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canlet.2015.11.034_bib0045","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4254\/wjh.v7.i3.362","article-title":"Diagnosis and treatment of hepatocellular carcinoma: an update","volume":"7","author":"Tejeda-Maldonado","year":"2015","journal-title":"World J. Hepatol"},{"key":"10.1016\/j.canlet.2015.11.034_bib0050","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-12-0151","article-title":"Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib","volume":"18","author":"Villanueva","year":"2012","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.11.034_bib0055","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nm.3679","article-title":"In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer","volume":"20","author":"Rudalska","year":"2014","journal-title":"Nat. Med"},{"key":"10.1016\/j.canlet.2015.11.034_bib0060","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/gutjnl-2012-303261","article-title":"Label-retaining liver cancer cells are relatively resistant to sorafenib","volume":"62","author":"Xin","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2015.11.034_bib0065","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/gutjnl-2013-304564","article-title":"Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?","volume":"62","author":"Berasain","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2015.11.034_bib0070","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-07-2248","article-title":"Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer","volume":"14","author":"Engelman","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.11.034_bib0075","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.canlet.2015.11.034_bib0080","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1039\/C5MB00322A","article-title":"Human genes with a greater number of transcript variants tend to show biological features of housekeeping and essential genes","volume":"11","author":"Ryu","year":"2015","journal-title":"Mol. Biosyst"},{"key":"10.1016\/j.canlet.2015.11.034_bib0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1749-6632.2009.05121.x","article-title":"MicroRNAs of the immune system: roles in inflammation and cancer","volume":"1183","author":"Davidson-Moncada","year":"2010","journal-title":"Ann. N. Y. Acad. Sci"},{"key":"10.1016\/j.canlet.2015.11.034_bib0090","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10555-009-9188-5","article-title":"MicroRNA function in cancer: oncogene or a tumor suppressor?","volume":"28","author":"Shenouda","year":"2009","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.canlet.2015.11.034_bib0095","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/onc.2010.487","article-title":"MicroRNA-221\/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways","volume":"30","author":"Rao","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.11.034_bib0100","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3892\/ijo.2014.2577","article-title":"miR222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma","volume":"45","author":"Liu","year":"2014","journal-title":"Int. J. Oncol"},{"key":"10.1016\/j.canlet.2015.11.034_bib0105","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/jcb.24665","article-title":"miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting p-type adenosine triphosphatase A (ATP7A)","volume":"115","author":"Song","year":"2014","journal-title":"J. Cell. Biochem"},{"key":"10.1016\/j.canlet.2015.11.034_bib0110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2014.07.004","article-title":"Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib","volume":"352","author":"Mao","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2015.11.034_bib0115","doi-asserted-by":"crossref","first-page":"8215","DOI":"10.1128\/JVI.02575-07","article-title":"Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells","volume":"82","author":"Chang","year":"2008","journal-title":"J. Virol"},{"key":"10.1016\/j.canlet.2015.11.034_bib0120","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/gb-2014-15-6-r79","article-title":"Genome-wide identification and functional analysis of Apobec-1-mediated C-to-U RNA editing in mouse small intestine and liver","volume":"15","author":"Blanc","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.canlet.2015.11.034_bib0125","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcb.20982","article-title":"Downregulation of miR-122 in the rodent and human hepatocellular carcinomas","volume":"99","author":"Kutay","year":"2006","journal-title":"J. Cell. Biochem"},{"key":"10.1016\/j.canlet.2015.11.034_bib0130","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/hep.23818","article-title":"Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development","volume":"52","author":"Xu","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.11.034_bib0135","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/hep.22806","article-title":"MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma","volume":"49","author":"Tsai","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.11.034_bib0140","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1038\/onc.2009.211","article-title":"Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties","volume":"28","author":"Coulouarn","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.11.034_bib0145","first-page":"160","article-title":"MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest","volume":"310","author":"Xu","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2015.11.034_bib0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2015.11.034_bib0155","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2015.11.034_bib0160","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/onc.2012.146","article-title":"IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR\/Akt pathway in non-small cell lung cancer","volume":"32","author":"Cort\u00e9s-Sempere","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.11.034_bib0165","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4161\/cbt.9.7.11267","article-title":"Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells","volume":"9","author":"Ma","year":"2010","journal-title":"Cancer Biol. Ther"},{"key":"10.1016\/j.canlet.2015.11.034_bib0170","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.2741\/2925","article-title":"The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance","volume":"13","author":"Casa","year":"2008","journal-title":"Front. Biosci"},{"key":"10.1016\/j.canlet.2015.11.034_bib0175","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/ncponc0934","article-title":"Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway \u2013 therapeutic perspectives in cancer","volume":"4","author":"Tao","year":"2007","journal-title":"Nat. Clin. Pract. Oncol"},{"key":"10.1016\/j.canlet.2015.11.034_bib0180","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrc2536","article-title":"Insulin and insulin-like growth factor signalling in neoplasia","volume":"8","author":"Pollak","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2015.11.034_bib0185","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.11.034_bib0190","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1210\/endo.142.3.7991","article-title":"Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor","volume":"142","author":"Navarro","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2015.11.034_bib0195","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/metabo5040571","article-title":"Cancer metabolism and drug resistance","volume":"5","author":"Rahman","year":"2015","journal-title":"Metabolites"},{"key":"10.1016\/j.canlet.2015.11.034_bib0200","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMc081780","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Spinzi","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2015.11.034_bib0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/annonc\/mdh006","article-title":"Effect of re-treatment with gefitinib (\u2018Iressa\u2019, ZD1839) after acquisition of resistance","volume":"15","author":"Kurata","year":"2004","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.canlet.2015.11.034_bib0210","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction","volume":"27","author":"Moriceau","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2015.11.034_bib0215","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-08-2023","article-title":"Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition","volume":"69","author":"Dallas","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.11.034_bib0220","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/hep.25745","article-title":"Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma","volume":"56","author":"Shan","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.11.034_bib0225","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.2011.244","article-title":"Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors","volume":"105","author":"Morgillo","year":"2011","journal-title":"Br. J. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515007247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515007247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T01:36:57Z","timestamp":1567388217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383515007247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0304383515007247"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2015.11.034","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS\/RAF\/ERK signaling pathways","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2015.11.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}